Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00773097|
Recruitment Status : Completed
First Posted : October 16, 2008
Results First Posted : February 3, 2014
Last Update Posted : February 16, 2018
The purpose of this study is to evaluate the immune response to MUC1 - poly-ICLC vaccine, an investigational or study vaccine. The MUC1 - poly-ICLC vaccine is being tested in persons with a history of advanced adenomatous polyps, the precursor to colorectal cancer. The MUC1 - poly-ICLC vaccine is being developed to prevent polyps from advancing into colon cancer and to prevent polyps from recurring.
MUC1 is mucus that is normally present on the lining of the human colon. However, MUC1 is expressed in a larger amount and in a modified form on adenomatous polyps and colorectal cancer. These changes in MUC1 are thought to be part of the process of progression from adenomas toward cancer. The goal of a vaccine is to help the immune system in the body identify the changes in MUC1 that accompany the progression to cancer and eliminate the abnormal cells that make abnormal MUC1.
|Condition or disease||Intervention/treatment||Phase|
|Risk for Colorectal Cancer||Biological: MUC1 - Poly ICLC||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||46 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of the MUC1 Peptide - Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma|
|Study Start Date :||October 2008|
|Primary Completion Date :||October 2011|
|Study Completion Date :||October 2012|
|Experimental: MUC1 Poly-ICLC||
Biological: MUC1 - Poly ICLC
The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
- Number of Participants With Anti Muc-1 Antibody [ Time Frame: 52 weeks ]Evaluation of the immune response to MUC1 peptide vaccine administered with Poly-ICLC, measured by Anti MUC1 antibody, in patients with a history of advanced colorectal adenoma.
- Number of Participants With Autoimmune Response to Muc-1 Vaccine [ Time Frame: 52 weeks ]Evaluate for autoimmune response by measuring the Anti-muc-1 IgG antibodies to the muc-1 vaccine.
- Number of Participants With Adverse Events Associated With the Study Agent [ Time Frame: 54 weeks ]Laboratory monitoring including Toxicity laboratory test or monitored through out the study up to week 54.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00773097
|United States, Pennsylvania|
|Digestive Disorders Clinic|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||Robert E Schoen||University of Pittsburgh|